{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:57:06Z","timestamp":1791493026015,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Current Research Grant"],"award-info":[{"award-number":["Current Research Grant"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06421-y","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:04:30Z","timestamp":1749074670000},"page":"3261-3269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deciphering clinical features and treatment patterns of thrombocytopenic myelodysplastic syndromes"],"prefix":"10.1007","volume":"104","author":[{"given":"Nicole","family":"Galli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Pettine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Croci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"11","key":"6421_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood [Internet] 140(11):1200\u20131228","journal-title":"Blood [Internet]"},{"issue":"4","key":"6421_CR2","first-page":"358","volume":"83","author":"GF Sanz","year":"1998","unstructured":"Sanz GF, Sanz MA, Greenberg PL (1998) Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 83(4):358\u2013368","journal-title":"Haematologica"},{"issue":"5","key":"6421_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1600-0609.2009.01299.x","volume":"83","author":"J Neukirchen","year":"2009","unstructured":"Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R et al (2009) Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. Eur J Haematol [Internet] 83(5):477\u2013482","journal-title":"Eur J Haematol [Internet]"},{"issue":"12","key":"6421_CR4","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood [Internet] 120(12):2454\u20132465","journal-title":"Blood [Internet]"},{"issue":"10","key":"6421_CR5","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1182\/blood-2011-12-399683","volume":"120","author":"B Will","year":"2012","unstructured":"Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R et al (2012) Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood [Internet] 120(10):2076\u20132086","journal-title":"Blood [Internet]"},{"issue":"1\u20132","key":"6421_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/10428190009060315","volume":"38","author":"W-K Hofmann","year":"2000","unstructured":"Hofmann W-K, Kalina U, Koschmieder S, Seipelt G, Hoelzer D, Ottmann OG (2000) Defective megakaryocytic development in myelodysplastic syndromes. Leuk Lymphoma [Internet] 38(1\u20132):13\u201319","journal-title":"Leuk Lymphoma [Internet]"},{"issue":"4","key":"6421_CR7","first-page":"486","volume":"12","author":"M Kitagawa","year":"1998","unstructured":"Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R (1998) Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leuk [Internet] 12(4):486\u2013492","journal-title":"Leuk [Internet]"},{"issue":"13","key":"6421_CR8","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1182\/blood-2006-05-023093","volume":"108","author":"TA Navas","year":"2006","unstructured":"Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P et al (2006) Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood [Internet] 108(13):4170\u20134177","journal-title":"Blood [Internet]"},{"issue":"1","key":"6421_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1046\/j.1365-2141.1997.3543166.x","volume":"99","author":"JA Adams","year":"1997","unstructured":"Adams JA, Liu Yin JA, Brereton ML, Briggs M, Burgess R, Hyde K (1997) The in vitro effect of pegylated Recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia. Br J Haematol [Internet] 99(1):139\u2013146","journal-title":"Br J Haematol [Internet]"},{"issue":"2","key":"6421_CR10","first-page":"95","volume":"71","author":"M Mittelman","year":"2000","unstructured":"Mittelman M, Zeidman A (2000) Platelet function in the myelodysplastic syndromes. Int J Hematol [Internet] 71(2):95\u201398","journal-title":"Int J Hematol [Internet]"},{"key":"6421_CR11","doi-asserted-by":"crossref","unstructured":"Barcellini W, Fattizzo B. Immune Phenomena in Myeloid Neoplasms: An \u201cEgg or Chicken\u201d Question. Front Immunol [Internet]. 2021 Sep 29;12.","DOI":"10.3389\/fimmu.2021.751630"},{"issue":"4","key":"6421_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.seminhematol.2012.07.004","volume":"49","author":"AR Parikh","year":"2012","unstructured":"Parikh AR, Olnes MJ, Barrett AJ (2012) Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte Globulin, cyclosporine, and alemtuzumab. Semin Hematol [Internet] 49(4):304\u2013311","journal-title":"Semin Hematol [Internet]"},{"issue":"28","key":"6421_CR13","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1200\/JCO.22.02699","volume":"41","author":"EN Oliva","year":"2023","unstructured":"Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V et al (2023) Eltrombopag for Low-Risk myelodysplastic syndromes with thrombocytopenia: interim results of a phase II, randomized, Placebo-Controlled clinical trial (EQOL-MDS). J Clin Oncol 41(28):4486\u20134496","journal-title":"J Clin Oncol"},{"issue":"12","key":"6421_CR14","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/cncr.28663","volume":"120","author":"A Giagounidis","year":"2014","unstructured":"Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U et al (2014) Results of a randomized, double-blind study of Romiplostim versus placebo in patients with low\/intermediate\u20101\u2013risk myelodysplastic syndrome and thrombocytopenia. Cancer [Internet] 120(12):1838\u20131846","journal-title":"Cancer [Internet]"},{"issue":"10","key":"6421_CR15","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al (2002) Randomized controlled trial of Azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and leukemia group B. J Clin Oncol [Internet] 20(10):2429\u20132440","journal-title":"J Clin Oncol [Internet]"},{"issue":"3","key":"6421_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of Azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol [Internet] 10(3):223\u2013232","journal-title":"Lancet Oncol [Internet]"},{"issue":"7","key":"6421_CR17","first-page":"1703","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leuk [Internet] 36(7):1703\u20131719","journal-title":"Leuk [Internet]"},{"issue":"2","key":"6421_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/ajcp\/aqad129","volume":"161","author":"J Wong","year":"2024","unstructured":"Wong J, Jackson R, Chen L, Song J, Pillai R, Afkhami M et al (2024) Determination of age-dependent bone marrow normocellularity. Am J Clin Pathol [Internet] 161(2):170\u2013176","journal-title":"Am J Clin Pathol [Internet]"},{"issue":"1","key":"6421_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12185-016-2081-4","volume":"105","author":"J Waisbren","year":"2017","unstructured":"Waisbren J, Dinner S, Altman J, Frankfurt O, Helenowski I, Gao J et al (2017) Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. Int J Hematol [Internet] 105(1):44\u201351","journal-title":"Int J Hematol [Internet]"},{"issue":"5","key":"6421_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/bjh.13902","volume":"175","author":"E Gyan","year":"2016","unstructured":"Gyan E, Andrieu V, Sanna A, Caille A, Schemenau J, Sudaka I et al (2016) Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by world health organization 2008 criteria and have favourable prognosis. Br J Haematol [Internet] 175(5):975\u2013979","journal-title":"Br J Haematol [Internet]"},{"issue":"3","key":"6421_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/RHU.0b013e3181776bde","volume":"14","author":"Y-C Lin","year":"2008","unstructured":"Lin Y-C, Liang T-H, Chang H-N, Lin J-S, Lin H-Y (2008) Beh\u00e7et disease associated with myelodysplastic syndrome. JCR J Clin Rheumatol [Internet] 14(3):169\u2013174","journal-title":"JCR J Clin Rheumatol [Internet]"},{"issue":"1","key":"6421_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ejh.13174","volume":"102","author":"N Wesner","year":"2019","unstructured":"Wesner N, Drevon L, Guedon A, Fraison JB, Trad S, Kahn JE et al (2019) Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case\u2010control study. Eur J Haematol [Internet] 102(1):63\u201369","journal-title":"Eur J Haematol [Internet]"},{"issue":"12","key":"6421_CR23","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s00277-022-04995-5","volume":"101","author":"B Katamesh","year":"2022","unstructured":"Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P et al (2022) Autoimmune manifestations in STAG2-mutated myeloid neoplasms. Ann Hematol [Internet] 101(12):2785\u20132787","journal-title":"Ann Hematol [Internet]"},{"issue":"1","key":"6421_CR24","first-page":"132","volume":"13","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo B, Serpenti F, Barcellini W, Caprioli C (2021) Hypoplastic myelodysplastic syndromes: just an overlap syndrome?? Cancers (Basel). [Internet] 13(1):132","journal-title":"[Internet]"},{"issue":"3","key":"6421_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1200\/JCO.2010.31.2686","volume":"29","author":"JR Passweg","year":"2011","unstructured":"Passweg JR, Giagounidis AAN, Simcock M, Aul C, Dobbelstein C, Stadler M et al (2011) Immunosuppressive therapy for patients with myelodysplastic syndrome: A prospective randomized multicenter phase III trial comparing antithymocyte Globulin plus cyclosporine with best supportive Care\u2014SAKK 33\/99. J Clin Oncol [Internet] 29(3):303\u2013309","journal-title":"J Clin Oncol [Internet]"},{"issue":"9","key":"6421_CR26","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1002\/cncr.10915","volume":"95","author":"C Selleri","year":"2002","unstructured":"Selleri C, Maciejewski JP, Catalano L, Ricci P, Andretta C, Luciano L et al (2002) Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia. Cancer [Internet] 95(9):1911\u20131922","journal-title":"Cancer [Internet]"},{"issue":"1","key":"6421_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3324\/haematol.10546","volume":"92","author":"W Barcellini","year":"2007","unstructured":"Barcellini W, Zaninoni A, Imperiali FG, Boschetti C, Colombi M, Iurlo A et al (2007) Anti-erythroblast autoimmunity in early myelodysplastic syndromes. Haematol [Internet] 92(1):19\u201326","journal-title":"Haematol [Internet]"},{"issue":"7","key":"6421_CR28","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/cancers13071532","volume":"13","author":"W Barcellini","year":"2021","unstructured":"Barcellini W, Giannotta JA, Fattizzo B (2021) Autoimmune complications in hematologic neoplasms. Cancers (Basel) [Internet] 13(7):1532","journal-title":"Cancers (Basel) [Internet]"},{"issue":"1","key":"6421_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000046525","volume":"105","author":"MCZ Novaretti","year":"2001","unstructured":"Novaretti MCZ, Sopelete CR, Velloso ERP, Rosa MFC, Dorlhiac-Llacer PE, Chamone DAF (2001) Immunohematological findings in myelodysplastic syndrome. Acta Haematol [Internet] 105(1):1\u20136","journal-title":"Acta Haematol [Internet]"},{"issue":"7","key":"6421_CR30","first-page":"1458","volume":"29","author":"I Ga\u00f1\u00e1n-G\u00f3mez","year":"2015","unstructured":"Ga\u00f1\u00e1n-G\u00f3mez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M et al (2015) Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leuk [Internet] 29(7):1458\u20131469","journal-title":"Leuk [Internet]"},{"key":"6421_CR31","doi-asserted-by":"crossref","unstructured":"Fattizzo B, Levati GV, Giannotta JA, Cassanello G, Cro LM, Zaninoni A, et al. Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience. Front Oncol [Internet]. 2022 Mar 22;12.","DOI":"10.3389\/fonc.2022.795955"},{"issue":"5","key":"6421_CR32","first-page":"452","volume":"21","author":"B Fattizzo","year":"2023","unstructured":"Fattizzo B, Serpenti F, Versino F, Cassanello G, Cro LM, Barbieri M et al (2023) Use of steroids in the management of low-risk myelodysplastic syndromes with autoimmune features. Blood Transfus 21(5):452\u2013460","journal-title":"Blood Transfus"},{"issue":"4","key":"6421_CR33","doi-asserted-by":"publisher","first-page":"E867","DOI":"10.1097\/HS9.0000000000000867","volume":"7","author":"M Riva","year":"2023","unstructured":"Riva M, Bosi A, Rizzo L, Mazzon F, Ferrari S, Lussana F et al (2023) Danazol treatment for thrombocytopenia in myelodysplastic syndromes: can an old-fashioned. Drug Be Effective? HemaSphere 7(4):E867","journal-title":"Drug Be Effective? HemaSphere"},{"issue":"13","key":"6421_CR34","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2013-07-512442","volume":"122","author":"V Santini","year":"2013","unstructured":"Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Ad\u00e8s L et al (2013) Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? Blood [Internet] 122(13):2286\u20132288","journal-title":"Blood [Internet]"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06421-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:38:13Z","timestamp":1757180293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06421-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6421"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06421-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients gave informed consent and the study was conducted according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}